CA2743837C - Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof - Google Patents

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof Download PDF

Info

Publication number
CA2743837C
CA2743837C CA2743837A CA2743837A CA2743837C CA 2743837 C CA2743837 C CA 2743837C CA 2743837 A CA2743837 A CA 2743837A CA 2743837 A CA2743837 A CA 2743837A CA 2743837 C CA2743837 C CA 2743837C
Authority
CA
Canada
Prior art keywords
implant
alpha
implants
release
adrenergic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2743837A
Other languages
English (en)
French (fr)
Other versions
CA2743837A1 (en
Inventor
Lon T. Spada
Alazar N. Ghebremeskel
Michael R. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2743837A1 publication Critical patent/CA2743837A1/en
Application granted granted Critical
Publication of CA2743837C publication Critical patent/CA2743837C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
CA2743837A 2008-11-17 2009-11-06 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof Active CA2743837C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/272,548 2008-11-17
US12/272,548 US9095506B2 (en) 2008-11-17 2008-11-17 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
PCT/US2009/063490 WO2010056598A2 (en) 2008-11-17 2009-11-06 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
CA2743837A1 CA2743837A1 (en) 2010-05-20
CA2743837C true CA2743837C (en) 2017-03-28

Family

ID=41698087

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2743837A Active CA2743837C (en) 2008-11-17 2009-11-06 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

Country Status (7)

Country Link
US (7) US9095506B2 (enExample)
EP (1) EP2355795B1 (enExample)
JP (2) JP5580832B2 (enExample)
AU (3) AU2009314266A1 (enExample)
CA (1) CA2743837C (enExample)
ES (1) ES2624448T3 (enExample)
WO (1) WO2010056598A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
WO2012112638A1 (en) * 2011-02-18 2012-08-23 Valeant International (Barbados) Srl Cross reference to related applications
US20120276186A1 (en) 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
JP5989780B2 (ja) 2011-09-14 2016-09-07 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
JP6138904B2 (ja) * 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
RU2652063C2 (ru) 2012-10-26 2018-04-24 Форсайт Вижн5, Инк. Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
EP2956096A1 (en) * 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
CA2908731A1 (en) 2013-04-12 2014-10-16 Allergan, Inc. Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
PT3062775T (pt) 2013-10-31 2018-03-06 Allergan Inc Implantes intraoculares contendo prostamida e métodos para a sua utilização
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
CA2949954A1 (en) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP3179982B1 (en) 2014-07-28 2023-07-19 Sun Pharma Advanced Research Company Ltd Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
CA2957764C (en) 2014-08-13 2019-07-02 The Johns Hopkins University Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
JP6847848B2 (ja) 2014-12-15 2021-03-24 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤、及び緑内障の治療におけるその使用方法
US20180008718A1 (en) 2015-01-20 2018-01-11 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
JP6827617B2 (ja) 2015-03-06 2021-02-10 アエリー ファーマシューティカルズ インコーポレイテッド 医療移植片送達の装置
WO2016149194A1 (en) 2015-03-13 2016-09-22 MAM Holdings of West Florida, L.L.C. Collagen compositions and uses for biomaterial implants
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
CN108883070A (zh) 2015-07-23 2018-11-23 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
JP6856620B2 (ja) * 2015-07-27 2021-04-07 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 薬剤搭載ナノ樹脂粒子
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
US9579350B1 (en) 2016-02-25 2017-02-28 MAM Holdings of West Florida, L.L.C. Human amniotic fluid preparation having long-term stability
WO2017151879A1 (en) 2016-03-02 2017-09-08 The Johns Hopkins University Compositions for sustained release of anti-glaucoma agents to control intraocular pressure
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
AU2017321980B2 (en) 2016-09-02 2020-04-30 Alcon Inc. Implant applicators
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
MX2020014160A (es) * 2018-06-25 2021-03-09 Titan Pharmaceuticals Inc Implantes para liberacion de sustancias farmaceuticas lipofilicas o anfifilicas.
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
KR20210135560A (ko) * 2019-03-05 2021-11-15 에어리 파마슈티컬즈, 인코포레이티드 안구 질환 또는 장애를 치료하는 약학 조성물
TW202216159A (zh) 2020-07-21 2022-05-01 美商歐樂根公司 具高負載前列腺素醯胺之眼內植入物
CA3267932A1 (en) 2022-10-05 2024-04-11 Mireca Medicines Gmbh MICROPARCEL AND IMPLANT FORMULATIONS FOR ANALOGUE CGMP THERAPY
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054102A (en) 1936-09-15 Voting machine
NL64744C (enExample) 1940-03-09
US2401708A (en) 1943-01-19 1946-06-04 Eastman Kodak Co Range finder
US2401408A (en) 1944-05-03 1946-06-04 Harold S Bixby Lock for fluorescent lamps
US2743837A (en) 1953-06-01 1956-05-01 Leon J Cook Lead sleeve expanding device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5264188A (en) 1991-01-22 1993-11-23 Phillips Petroleum Company Multi-stage hydrotreating process and apparatus
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
WO1998010758A1 (en) 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
KR20010014384A (ko) 1997-07-02 2001-02-26 모리타 다카카즈 폴리락트산 공막 플러그
JP2001513369A (ja) 1997-08-11 2001-09-04 アラーガン・セイルズ・インコーポレイテッド 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法
JP2003511204A (ja) 1999-10-21 2003-03-25 アルコン，インコーポレイティド テノン下薬剤送出
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
WO2002058730A2 (en) 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
JP5170935B2 (ja) 2001-11-14 2013-03-27 デュレクト コーポレーション 注入可能なデポー組成物
AU2003214133A1 (en) 2002-03-18 2003-09-29 Novartis Ag Topical composition comprising a cyclofructan, a carrier and a drug
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ES2295647T3 (es) 2002-07-15 2008-04-16 Alcon, Inc. Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
CA2501348A1 (en) * 2002-10-08 2004-04-22 Allergan, Inc. Treatment of dementia and parkinson's disease
RU2355385C2 (ru) 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
DK1592408T3 (da) 2003-01-24 2010-01-04 Psivida Inc Indretning med depotvirkning og fremgangsmåde til okulær indgivelse af adrenergt midler
JP2005035235A (ja) * 2003-07-18 2005-02-10 Noritsu Koki Co Ltd 画像露光装置
US20050131372A1 (en) * 2003-12-10 2005-06-16 Kimberly-Clark Worldwide, Inc. Absorbent articles with removable protective wing portions
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244471A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7135391B2 (en) * 2004-05-21 2006-11-14 International Business Machines Corporation Polycrystalline SiGe junctions for advanced devices
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US11851905B2 (en) 2019-04-23 2023-12-26 Raily S.R.L. Modular railing suitable for variable installation slopes
US11902105B2 (en) 2022-05-24 2024-02-13 Red Hat, Inc. Interactive graphical user interface for visualizing flow data in a programmable network switch

Also Published As

Publication number Publication date
JP5580832B2 (ja) 2014-08-27
US20230285279A1 (en) 2023-09-14
ES2624448T3 (es) 2017-07-14
AU2018202557A1 (en) 2018-05-10
US10842739B2 (en) 2020-11-24
US9522113B2 (en) 2016-12-20
US20210161809A1 (en) 2021-06-03
JP2012509264A (ja) 2012-04-19
US20170100334A1 (en) 2017-04-13
AU2009314266A1 (en) 2010-05-20
US9861576B2 (en) 2018-01-09
US20100124565A1 (en) 2010-05-20
WO2010056598A3 (en) 2010-12-23
CA2743837A1 (en) 2010-05-20
AU2018202557B2 (en) 2020-02-27
JP2014184348A (ja) 2014-10-02
EP2355795B1 (en) 2017-01-04
EP2355795A2 (en) 2011-08-17
US20200069578A1 (en) 2020-03-05
US10471004B2 (en) 2019-11-12
WO2010056598A2 (en) 2010-05-20
US20160030334A1 (en) 2016-02-04
US20180353426A1 (en) 2018-12-13
US9095506B2 (en) 2015-08-04
AU2016204582A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
US20230285279A1 (en) Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US9161938B2 (en) Sustained release intraocular implants and methods for treating ocular vasculopathies
US8715709B2 (en) Sustained release intraocular implants and methods for treating ocular neuropathies
US8293210B2 (en) Sustained release intraocular implants and methods for preventing retinal dysfunction
US20060233860A1 (en) Alpha-2 agonist polymeric drug delivery systems

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141024

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251218

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203